Bionik Laboratories Corp. · OTC:BNKL
Bionik Laboratories — Investor Presentation (March 2016)
23 slides from Bionik Laboratories's investor presentation, Mar 30, 2016
Slide 1: Corporate Presentation March 2016
www.bioniklabs.com OTCQX:BNKL Corporate Presentation March 2016
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward - looking statements relating to future events or the future financial performance and operations of Bionik . Forward - looking statements, which involve assumptions and describe Bionik’s intent, belief or current expectations about its business op
Slide 3: Bionik Overview
Bionik Overview • Pioneering medical device and robotics company with a focus in developing transformational technologies and solutions for individuals with neurological disorders • Recent planned acquisition of Interactive Motion Technologies to add 3 commercial products with immediate revenue; IMT
Slide 4: Planned Acquisition of IMT Expected to Position Bionik as a Leading Robotics and Medical Device Company
Planned Acquisition of IMT Expected to Position Bionik as a Leading Robotics and Medical Device Company 4 • Robotics company developing solutions for individuals with neurological disorders • Primary program ARKE • Global pioneer in robotic rehabilitation therapy for central nervous system disorders
Slide 5: Post Acquisition Commercial and Development Product Portfolio
Post Acquisition Commercial and Development Product Portfolio 5 Product Optimization Pre - clinical Clinical Approval InMotion Arm™ InMotion Hand™ InMotion Wrist™ ARKE™ InMotion Ankle™ Lower Body Robot Internal R&D
Slide 6: IMT Upper Extremity Commercial-Stage Product Line
IMT Upper Extremity Commercial - Stage Product Line • InMotion ARM • Designed to rehabilitate stroke patients with upper body neurological limitations • Evidence based, intelligent, interactive technology capable of continuously adapting to and challenging the patient's ability • Allows the clinicia
Slide 7: IMT Lower Body Development-Stage Product Pipeline
IMT Lower Body Development - Stage Product Pipeline • InMotion ANKLE™ • Exoskeletal robotic system using the same design principles in upper extremity rehabilitation • Designed in close collaboration with the Newman Laboratory for Biomechanics and Human Rehabilitation at MIT • Currently available in
Slide 8: ARKE
ARKE A robotic lower body exoskeleton designed to allow paraplegics as well as other wheelchair users, the ability to rehabilitate through walking TM
Slide 9: ARKE: Product Details
ARKE: Product Details • Sensors throughout the device sense body movement and trigger motion • Constructed with carbon fiber, aluminum and steel • Fully customizable to fit patients of all heights and weights • Connects to Bionik’s cloud software where data is analyzed and displayed back to the phys
Slide 10: Collaboration with IBM Further Differentiates ARKE from Competitors
Collaboration with IBM Further Differentiates ARKE from Competitors 10 Data is collected from ARKE and analyzed utilizing IBM’s Cognitive Computing Infrastructure and sophisticated machine learning algorithms Analytical data is used to identify correlations between different rehabilitation regimens
Slide 11: ARKE: Healthcare Cost – SCI & Stroke
ARKE: Healthcare Cost – SCI & Stroke Spinal Cord Injuries [1] • Length of initial hospitalization following injury in acute care units: 11 days • Average stay in - patient rehabilitation unit: 36 days • Average Lifetime Costs (3) : Stroke • In the US, heart attack and stroke costs are estimated at o
Slide 12: ARKE: Sizing the Market
ARKE: Sizing the Market • There are approximately 276,000 people living with SCI in the USA, with an estimated annual 12,500 new cases. (1) Across the G20 this translates to an estimated 4,000,000 existing SCI and 180,000 new cases annually. • Of the global, annual, 16,000,000 stroke cases, 5,000,00
Slide 13: Competitive Landscape for ARKE
Competitive Landscape for ARKE Company & Device Selling Price Status Tech Points REWALK (RWLK: NASDAQ) - Rewalk Personal 6.0 System $ 69,500 in USA € 52,500 in EU - CE Marks and FDA cleared for personal and rehabilitation use - FDA De Novo created PHL category; a new classification paradigm for powe
Slide 14: ARKE: Business Model
ARKE: Business Model 14 In - Patient Rehab • Lease/Rental model • Monthly fee to the hospital/clinic for use of the product Out - Patient Rehab • Revenue share or Lease/Rental model • Percentage of the per session therapy to Bionik Home Use • Rental or direct product sale • ARKE revenue can be gener
Slide 15: ARKE Reimbursement: Landmark Policy Granted Dec. 2015
ARKE Reimbursement: Landmark Policy Granted Dec. 2015 • Currently no universal coverage; however successful reimbursement on a case - by - case has been achieved • Etiology of injury impacts financing plan – e.g. vehicle accidents (automobile liability and Personal Injury Protection); workplace (wor
Slide 16: ARKE: Path to Commercialization
ARKE: Path to Commercialization 16 Market Canada European Union United States Regulating Authority Health Canada Medical Device Regulations (MDR) Notified Body Medical Device Directive (MDD) Food & Drug Administration 21 CFR Classification Class I Class II a Class II w/ special controls License Aven
Slide 17: Robust Intellectual Property
Robust Intellectual Property Area Of IP Status Filing Year Algorithms & Control Systems Filed US & International 2012 Sensory Technology Filed US & International 2012 Robotics Filed US & International 2012 Robotics Filed US & International 2012 Robotics Filed US & International 2012 Robotics US Prov
Slide 18: Growth Strategy Focused on Further Pipeline Expansion
University Networks Expanded and Focused Development Programs In - house R&D Licensing / Acquisitions Industry Partners MIT Technology Growth Strategy Focused on Further Pipeline Expansion • Leverage our in - depth research and development relationships within the space along with our relationship w
Slide 19: Completion of Acquisition of IMT Creates World Class Management Team
Completion of Acquisition of IMT Creates World Class Management Team • Peter Bloch, CPA, CA – Chief Executive Officer • Over 25 years of executive management experience with proven track record of building public and private technology companies. Former CFO and joint Interim CEO of Sanofi Canada, CF
Slide 20: Board and Advisors Strengthens Capabilities
Board and Advisors Strengthens Capabilities Advisors • Neville Hogan, Ph.D., M.S, M.E.* • Sun Jae Professor of Mechanical Engineering, Professor of Brain and Cognitive Sciences, and Director of the Newman Laboratory for Biomechanics and Human Rehabilitation at MIT • Gary Henley • Significant medtech
Slide 21: Financial Snapshot
Financial Snapshot - OTCQX: BNKL Stock Ticker Symbol OTCQX: BNKL Market Capitalization as of March 24, 2016 $71.9 M Shares Outstanding 72.6 M* Warrants at exercise price of $1.40 16.4 M Warrants at exercise price of $0.80 1.49 M R ecent financings: February - July , 2015 $13.1 M Cash as of December
Slide 22: Near-term Milestones
Near - term Milestones 22 201 6 H1 201 6 H2 201 7 H1 201 7 H 2 Pre - clinical verification testing gen 2 - ARKE Clinical evaluations - ARKE First clinical data readout - ARKE Targeted Health Canada MDEL & CE Mark Filings - ARKE Expected Health Canada license & CE Marks Registration - ARKE Formal Cli
Slide 23: www.bioniklabs.com
www.bioniklabs.com OTCQX:BNKL Corporate Presentation
Bionik Laboratories — Investor Presentation (March 2016) on 6ix